About Breast Cancer

Breast Cancer Basics

Get an overview of the different types of breast cancer and where they start.

- What Is Breast Cancer?
- What Causes Breast Cancer?

Types of Breast Cancer

There are several types of breast cancer. The type of breast cancer you have depends on where in the breast it started and other factors.

- Types of Breast Cancer Overview
- Ductal Carcinoma in Situ (DCIS)
- Invasive Breast Cancer (IDC/ILC)
- Triple-negative Breast Cancer
- Angiosarcoma of the Breast
- Inflammatory Breast Cancer
- Paget Disease of the Breast

Research and Statistics

See the latest estimates for new cases and deaths of breast cancer in the US and what research is being done.

- Key Statistics for Breast Cancer
- What’s New in Breast Cancer Research?
What Is Breast Cancer?

Breast cancer is a type of cancer that starts in the breast. It can start in one or both breasts.

Cancer starts when cells begin to grow out of control. (To learn more about how cancers start and spread, see What Is Cancer?)

Breast cancer occurs almost entirely in women, but men can get breast cancer, too.

It’s important to understand that most breast lumps are benign and not cancer (malignant). Non-cancer breast tumors are abnormal growths, but they do not spread outside of the breast. They are not life threatening, but some types of benign breast lumps can increase a woman’s risk of getting breast cancer. Any breast lump or change needs to be checked by a health care professional to find out if it is benign or malignant (cancer) and if it might affect yours future cancer risk. See Non-cancerous Breast Conditions to learn more.

Where breast cancer starts

Breast cancers can start from different parts of the breast. The breast is an organ that sits on top of the upper ribs and chest muscles. There is a left and right breast and each one has mainly glands, ducts, and fatty tissue. In women, the breast makes and delivers milk to feed newborns and infants. The amount of fatty tissue in the breast determines the size of each breast.

The breast has different parts:

- **Lobules** are the glands that make breast milk. Cancers that start here are called **lobular cancers**.
- **Ducts** are small canals that come out from the lobules and carry the milk to the nipple. This is the most common place for breast cancer to start. Cancers that start here are called **ductal cancers**.
- The **nipple** is the opening in the skin of the breast where the ducts come together and turn into larger ducts so the milk can leave the breast. The nipple is surrounded by slightly darker thicker skin called the **areola**. A less common type of breast cancer called Paget disease of the breast can start in the nipple.
- The **fat and connective tissue (stroma)** surround the ducts and lobules and help keep them in place. A less common type of breast cancer called phyllodes tumor can start in the nipple.
can start in the stroma.

- **Blood vessels** and **lymph vessels** are also found in each breast. Angiosarcoma is a less common type of breast cancer that can start in the lining of these vessels. The lymph system is described below.

A small number of cancers start in other tissues in the breast. These cancers are called sarcomas and lymphomas and are not really thought of as breast cancers.

To learn more, see Types of Breast Cancer.

**How breast cancer spreads**

Breast cancer can spread when the cancer cells get into the blood or lymph system and then are carried to other parts of the body.
The lymph (or lymphatic) system is a part of your body's immune system. It is a network of lymph nodes (small, bean-sized glands), ducts or vessels, and organs that work together to collect and carry clear lymph fluid through the body tissues to the blood. The clear lymph fluid inside the lymph vessels contains tissue by-products and waste material, as well as immune system cells.

The lymph vessels carry lymph fluid away from the breast. In the case of breast cancer, cancer cells can enter those lymph vessels and start to grow in lymph nodes. Most of the lymph vessels of the breast drain into:

- Lymph nodes under the arm (axillary lymph nodes)
- Lymph nodes inside the chest near the breastbone (internal mammary lymph nodes)
- Lymph nodes around the collar bone (supraclavicular [above the collar bone] and infraclavicular [below the collar bone] lymph nodes)

If cancer cells have spread to your lymph nodes, there is a higher chance that the cells could have traveled through the lymph system and spread (metastasized) to other parts of your body. Still, not all women with cancer cells in their lymph nodes develop metastases, and some women with no cancer cells in their lymph nodes might develop metastases later.
There are many different types of breast cancer. The type is determined by the specific kind of cells in the breast that are affected. Most breast cancers are carcinomas. The
most common breast cancers such as ductal carcinoma in situ (DCIS) and invasive carcinoma are adenocarcinomas, since the cancers start in the gland cells in the milk ducts or the lobules (milk-producing glands). Other kinds of cancers can grow in the breast, like angiosarcoma or sarcoma, but are not considered breast cancer since they start in different cells of the breast.

Breast cancers are also classified by certain types of proteins or genes each cancer might make. After a biopsy is done, breast cancer cells are tested for proteins called estrogen receptors and progesterone receptors, and the HER2 gene or protein. The tumor cells are also closely looked at in the lab to find out what grade it is. The specific proteins found and the tumor grade can help decide the stage of the cancer and treatment options.

To learn more about the specific tests done on breast cancer cells, see Understanding a Breast Cancer Diagnosis.

Hyperlinks

1. www.cancer.org/treatment/understanding-your-diagnosis/what-is-cancer.html

References

What Causes Breast Cancer?

We don’t know what causes each case of breast cancer. But we do know many of the risk factors for these cancers (see Lifestyle-related Breast Cancer Risk Factors and Breast Cancer Risk Factors You Cannot Change). For example, lifestyle-related risk factors, such as what you eat and how much you exercise, can increase your chance of developing breast cancer, but it’s not yet known exactly how some of these risk factors cause normal cells to become cancer. Hormones also seem to play a role in many cases of breast cancer, but just how this happens is not fully understood.

We do know that normal breast cells can become cancer because of changes or mutations in genes. But only about 1 in 10 breast cancers (10%) are linked with known abnormal genes that are passed on from parents (inherited). Many genes have not yet been discovered, so women with a family history of breast cancer might have inherited an abnormal gene that doesn’t show on a genetic test. Most breast cancers (about 90%) develop from acquired (not inherited) gene changes that have not yet been identified.

How gene changes can lead to breast cancer

Genes control how our cells function. They are made up of a chemical called DNA, which comes from both our parents. DNA affects more than just how we look; it also can influence our risk for developing certain diseases, including some kinds of cancer.
Normal cells have genes called **proto-oncogenes**, which help control when the cells grow, divide to make new cells, or stay alive. If a proto-oncogene is mutated (changed) in a certain way, it becomes an **oncogene**. Cells that have these mutated oncogenes can become cancer.

Normal cells also have genes called **tumor suppressor genes**, which help control how often normal cells divide in two, repair DNA mistakes, or cause cells to die at the right time. If a cell has a mutated tumor suppressor gene, then the cell can turn into cancer.

Cancers can be caused by gene changes that turn on oncogenes or turn off tumor suppressor genes. **Changes in many different genes are usually needed to cause breast cancer.**

### Inherited gene changes

**Some gene changes (mutations) are inherited or passed to you from your parents.** This means the mutations are in all your cells when you are born.

Certain inherited gene changes can greatly increase the risk for developing certain cancers and are linked to many of the cancers that run in some families. For instance, the **BRCA** genes (**BRCA1** and **BRCA2**) are tumor suppressor genes. When one of these genes changes, it no longer suppresses abnormal cell growth, and cancer is more likely to develop. A change in one of these genes can be passed from a parent to a child.

Women have already begun to benefit from advances in understanding the genetic basis of breast cancer. **Genetic testing** can identify some women who have inherited mutations in the **BRCA1** or **BRCA2** tumor suppressor genes as well as other less common genes such as **PALB2**, **ATM**, or **CHEK2**. These women can then take steps to reduce their risk of breast cancer by increasing awareness of their breasts and following appropriate **screening recommendations** to help find cancer at an earlier, more treatable stage. Since these mutations are also often associated with other cancers (besides breast), women with these mutations might also consider early screening and preventive actions for other cancers.

Mutations in tumor suppressor genes like the **BRCA** genes are considered “high penetrance” because they often lead to cancer. Although many women with high penetrance mutations develop cancer, most cases of cancer (including breast cancer) are not caused by this kind of mutation.

More often, low-penetrance mutations or gene variations are a factor in cancer.
development. Each of these may have a small effect on cancer occurring in any one person, but the overall effect on the population can be large because the mutations are common, and people often have more than one at the same time. The genes involved can affect things like hormone levels, metabolism, or other factors that impact risk for breast cancer. These genes might also cause much of the risk of breast cancer that runs in families.

**Acquired gene changes**

**Most gene mutations linked to breast cancer are acquired.** This means the change takes place in breast cells during a person's life rather than having been inherited or born with them. Acquired DNA mutations take place over time and are only in the breast cancer cells.

These acquired mutations of oncogenes and/or tumor suppressor genes may result from other factors, like radiation or cancer-causing chemicals. But some gene changes may just be random events that sometimes happen inside a cell, without having an outside cause. So far, the causes of most acquired mutations that could lead to breast cancer are still unknown. Most breast cancers have several acquired gene mutations.

**Hyperlinks**


**References**
Types of Breast Cancer

There are many types of breast cancer, and many different ways to describe them. It’s easy to get confused.

A breast cancer’s type is determined by the specific cells in the breast that become cancer.

Ductal or lobular carcinoma

Most breast cancers are carcinomas, which are tumors that start in the epithelial cells that line organs and tissues throughout the body. When carcinomas form in the breast, they are usually a more specific type called adenocarcinoma, which starts in cells in the ducts (the milk ducts) or the lobules (glands in the breast that make milk).
In situ vs. invasive breast cancers

The type of breast cancer can also refer to whether the cancer has spread or not. **In situ** breast cancer (**ductal carcinoma in situ or DCIS**) is a pre-cancer that starts in a milk duct and has not grown into the rest of the breast tissue. The term **invasive (or infiltrating)** breast cancer is used to describe any type of breast cancer that has spread (invaded) into the surrounding breast tissue.

Ductal carcinoma in situ (DCIS)

Ductal carcinoma in situ (DCIS; also known as **intraductal carcinoma**) is a non-invasive or pre-invasive breast cancer.

Invasive breast cancer (ILC or IDC)

Invasive (or infiltrating) breast cancer has spread into surrounding breast tissue. The most common types are **invasive ductal carcinoma** and **invasive lobular carcinoma**. Invasive ductal carcinoma makes up about 70-80% of all breast cancers.

Special types of invasive breast cancers

Some invasive breast cancers have special features or develop in different ways that influence their treatment and outlook. These cancers are less common but can be more serious than other types of breast cancer.

Triple-negative breast cancer

Triple-negative breast cancer is an aggressive type of invasive breast cancer in which the cancer cells don’t have estrogen or progesterone receptors (ER or PR) and also don’t make any or too much of the protein called HER2. (The cells test “negative” on all 3 tests.) It accounts for about 15% of all breast cancers and can be a difficult cancer to treat.

Inflammatory breast cancer

Inflammatory breast cancer is an aggressive type of invasive breast cancer in which cancer cells block lymph vessels in the skin, causing the breast to look "inflamed." It is rare and accounts for about 1% to 5% of all breast cancers.

Less common types of breast cancer

There are other types of breast cancers that start to grow in other types of cells in the
breast. These cancers are much less common, and sometimes need different types of treatment.

**Paget disease of the breast**

Paget disease of the breast is rare, accounting for only about 1-3% of all cases of breast cancer. It starts in the breast ducts and spreads to the skin of the nipple and then to the areola (the dark circle around the nipple).

**Angiosarcoma**

Sarcomas of the breast are rare making up less than 1% of all breast cancers. Angiosarcoma starts in cells that line blood vessels or lymph vessels. It can involve the breast tissue or the skin of the breast. Some may be related to prior radiation therapy in that area.

**Phyllodes tumor**¹

Phyllodes tumors are rare breast tumors. They develop in the connective tissue (stroma) of the breast, in contrast to carcinomas, which develop in the ducts or lobules. Most are benign, but there are others that are malignant (cancer).

**Hyperlinks**


**References**


Ductal Carcinoma In Situ (DCIS)

About 1 in 5 new breast cancers will be ductal carcinoma in situ (DCIS). Nearly all women with this early stage of breast cancer can be cured.
DCIS is also called *intraductal carcinoma* or *stage 0 breast cancer*. DCIS is a non-invasive or pre-invasive breast cancer. This means the cells that line the ducts have changed to cancer cells but they have not spread through the walls of the ducts into the nearby breast tissue.

Because DCIS hasn’t spread into the breast tissue around it, it can’t spread (metastasize) beyond the breast to other parts of the body.

However, DCIS can sometimes become an invasive cancer. At that time, the cancer has spread out of the duct into nearby tissue, and from there, it could metastasize to other parts of the body.
Right now, there’s no good way to know for sure which will become invasive cancer and which ones won’t, so almost all women with DCIS will be treated.

**Treating DCIS**

In most cases, a woman with DCIS can choose between breast-conserving surgery (BCS) and simple mastectomy. Radiation is usually given after BCS. Tamoxifen or an aromatase inhibitor after surgery might also be an option if the DCIS is hormone-receptor positive\(^1\).

See [Treatment for Ductal Carcinoma in Situ (DCIS)\(^2\)] to learn more.

**Hyperlinks**


**References**


Invasive Breast Cancer (IDC/ILC)

Breast cancers that have spread into surrounding breast tissue are known as invasive breast cancers.

Most breast cancers are invasive, but there are different types of invasive breast cancer. The two most common are invasive ductal carcinoma and invasive lobular carcinoma.

Inflammatory breast cancer is also a type of invasive breast cancer.

Invasive (infiltrating) ductal carcinoma (IDC)

This is the most common type of breast cancer. About 8 in 10 invasive breast cancers are invasive (or infiltrating) ductal carcinomas (IDC).

IDC starts in the cells that line a milk duct in the breast. From there, the cancer breaks through the wall of the duct, and grows into the nearby breast tissues. At this point, it may be able to spread (metastasize) to other parts of the body through the lymph system and bloodstream.

Invasive lobular carcinoma (ILC)

About 1 in 10 invasive breast cancers is an invasive lobular carcinoma (ILC).
ILC starts in the breast glands that make milk (lobules). Like IDC, it can spread (metastasize) to other parts of the body. Invasive lobular carcinoma may be harder to detect on physical exam and imaging, like mammograms, than invasive ductal carcinoma. And compared to other kinds of invasive carcinoma, it is more likely to affect both breasts. About 1 in 5 women with ILC might have cancer in both breasts at the time they are diagnosed.

**Less common types of invasive breast cancer**

There are some special types of breast cancer that are sub-types of invasive carcinoma. They are less common than the breast cancers named above and each typically make up fewer than 5% of all breast cancers. These are often named after features of the cancer cells, like the ways the cells are arranged.

Some of these may have a better prognosis than the more common IDC. These include:

- Adenoid cystic (or adenocystic) carcinoma
- Low-grade adenosquamous carcinoma (this is a type of metaplastic carcinoma)
- Medullary carcinoma
- Mucinous (or colloid) carcinoma
- Papillary carcinoma
- Tubular carcinoma

Some sub-types have the same or maybe worse prognoses than IDC. These include:

- Metaplastic carcinoma (most types, including spindle cell and squamous, except low grade adenosquamous carcinoma)
- Micropapillary carcinoma
- Mixed carcinoma (has features of both invasive ductal and invasive lobular)

In general, all of these sub-types are still treated like IDC.

**Treating invasive breast cancer**

Treatment of invasive breast cancer depends on how advanced the cancer is (the stage of the cancer) and other factors. Most women will have some type of surgery to remove the tumor. Depending on the type of breast cancer and how advanced it is, you might need other types of treatment as well, either before or after surgery, or sometimes both.
See [Treating Breast Cancer](#) for details on different types of treatment, as well as common treatment approaches based on the stage or other factors.

**Hyperlinks**


**References**


---

**Triple-negative Breast Cancer**

Triple-negative breast cancer (TNBC) accounts for about 10-15% of all breast cancers. The term **triple-negative breast cancer** refers to the fact that the cancer cells don’t
have estrogen or progesterone receptors\(^1\) (ER or PR) and also don’t make any or too much of the protein called HER\(^2\). (The cells test "negative" on all 3 tests.) These cancers tend to be more common in women younger than age 40, who are Black, or who have a BRCA\(^1\) mutation.

Triple-negative breast cancer differs from other types of invasive breast cancer in that they grow and spread faster, have limited treatment options, and have a worse prognosis (outcome).

**Signs and symptoms of triple-negative breast cancer**

Triple-negative breast cancer can have the same signs and symptoms\(^3\) as other common types of breast cancer.

**How is triple-negative breast cancer diagnosed?**

Once a breast cancer diagnosis has been made using imaging tests and a biopsy\(^4\), the cancer cells will be checked for certain proteins. If the cells do not have estrogen or progesterone receptors (ER or PR), and also do not make any or too much of the HER2 protein, the cancer is considered to be triple-negative breast cancer.

**Survival rates for triple-negative breast cancer**

Triple-negative breast cancer (TNBC) is considered an aggressive cancer because it grows quickly, is more likely to have spread at the time it’s found, and is more likely to come back after treatment than other types of breast cancer. The outlook is generally not as good as it is for other types of breast cancer.

Survival rates can give you an idea of what percentage of people with the same type and stage of cancer are still alive a certain amount of time (usually 5 years) after they were diagnosed. They can’t tell you how long you will live, but they may help give you a better understanding of how likely it is that your treatment will be successful.

**Keep in mind that survival rates are estimates and are often based on previous outcomes of large numbers of people who had a specific cancer, but they can’t predict what will happen in any particular person’s case. These statistics can be confusing and may lead you to have more questions. Talk with your doctor about how these numbers may apply to you, as he or she is familiar with your situation.**

**What is a 5-year relative survival rate?**
A **relative survival rate** compares women with the same type and stage of breast cancer to women in the overall population. For example, if the **5-year relative survival rate** for a specific stage of breast cancer is 90%, it means that women who have that cancer are, on average, about 90% as likely as women who don’t have that cancer to live for at least 5 years after being diagnosed.

**Where do these numbers come from?**

The American Cancer Society relies on information from the Surveillance, Epidemiology, and End Results Program (SEER) database, maintained by the National Cancer Institute (NCI), to provide survival statistics for different types of cancer.

The SEER database tracks 5-year relative survival rates for breast cancer in the United States, based on how far the cancer has spread. The SEER database, however, does not group cancers by **AJCC TNM stages** (stage 1, stage 2, stage 3, etc.). Instead, it groups cancers into localized, regional, and distant stages:

- **Localized:** There is no sign that the cancer has spread outside of the breast.
- **Regional:** The cancer has spread outside the breast to nearby structures or lymph nodes.
- **Distant:** The cancer has spread to distant parts of the body such as the lungs, liver, or bones.

### 5-year relative survival rates for triple-negative breast cancer

These numbers are based on women diagnosed with triple-negative breast cancer between 2010 and 2016.

<table>
<thead>
<tr>
<th>SEER Stage</th>
<th>5-year Relative Survival Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Localized</td>
<td>91%</td>
</tr>
<tr>
<td>Regional</td>
<td>65%</td>
</tr>
<tr>
<td>Distant</td>
<td>12%</td>
</tr>
<tr>
<td>All stages combined</td>
<td>77%</td>
</tr>
</tbody>
</table>

**Understanding the numbers**
Women now being diagnosed with triple negative breast cancer may have a better outlook than these numbers show. Treatments improve over time, and these numbers are based on women who were diagnosed and treated at least four to five years earlier.

These numbers apply only to the stage of the cancer when it is first diagnosed. They do not apply later on if the cancer grows, spreads, or comes back after treatment.

These numbers don’t take everything into account. Survival rates are grouped based on how far the cancer has spread, but your age, overall health, how well the cancer responds to treatment, tumor grade, and other factors can also affect your outlook.

Treating triple-negative breast cancer

Triple-negative breast cancer has fewer treatment options than other types of invasive breast cancer. This is because the cancer cells do not have the estrogen or progesterone receptors or enough of the HER2 protein to make hormone therapy or targeted HER2 drugs work. Because hormone therapy and anti-HER2 drugs are not choices for women with triple-negative breast cancer, chemotherapy is often used.

If the cancer has not spread to distant sites, surgery is an option. Chemotherapy might be given first to shrink a large tumor, followed by surgery. Chemotherapy is often recommended after surgery to reduce the chances of the cancer coming back. Radiation might also be an option depending on certain features of the tumor and the type of surgery you had.

In cases where the cancer has spread to other parts of the body (stage IV), platinum chemotherapy, targeted drugs like a PARP inhibitor, or antibody-drug conjugate, or immunotherapy with chemotherapy might be considered.

For details, see Treatment of Triple-negative Breast Cancer.

Hyperlinks


References


Inflammatory Breast Cancer

Inflammatory breast cancer (IBC) is rare and accounts for only 1% to 5% of all breast cancers. Although it is a type of invasive ductal carcinoma, its symptoms, outlook, and treatment are different. IBC causes symptoms of breast inflammation like swelling and redness, which is caused by cancer cells blocking lymph vessels in the skin causing the breast to look "inflamed."

Inflammatory breast cancer (IBC) differs from other types of breast cancer in many ways:

- IBC doesn't look like a typical breast cancer. It often does not cause a breast lump, and it might not show up on a mammogram. This makes it harder to diagnose.
- IBC tends to occur in younger women (younger than 40 years of age).
- Black women appear to develop IBC more often than white women.
- IBC is more common among women who are overweight or obese.
- IBC tends to be more aggressive—it grows and spreads much more quickly—than more common types of breast cancer.
- IBC is always at a locally advanced stage when it’s first diagnosed because the breast cancer cells have grown into the skin. (This means it is at least stage III.)
- In about 1 of every 3 cases, IBC has already spread (metastasized) to distant parts of the body when it is diagnosed. This makes it harder to treat successfully.
- Women with IBC tend to have a worse prognosis (outcome) than women with other common types of breast cancer.

Signs and symptoms of inflammatory breast cancer

Inflammatory breast cancer (IBC) causes a number of signs and symptoms, most of which develop quickly (within 3-6 months), including:
- Swelling (edema) of the skin of the breast
- Redness involving more than one-third of the breast
- Pitting or thickening of the skin of the breast so that it may look and feel like an orange peel
- A retracted or inverted nipple
- One breast looking larger than the other because of swelling
- One breast feeling warmer and heavier than the other
- A breast that may be tender, painful or itchy
- Swelling of the lymph nodes under the arms or near the collarbone

Inflammatory breast cancer

If you have any of these symptoms, it does not mean that you have IBC, but you should see a doctor right away. Tenderness, redness, warmth, and itching are also common symptoms of a breast infection or inflammation, such as mastitis if you’re pregnant or breastfeeding. Because these problems are much more common than IBC, your doctor
might suspect infection at first as a cause and treat you with antibiotics.

Treatment with antibiotics may be a good first step, but if your symptoms don’t get better in 7 to 10 days, more tests need to be done to look for cancer. Let your doctor know if it doesn't help, especially if the symptoms get worse or the affected area gets larger. The possibility of IBC should be considered more strongly if you have these symptoms and are not pregnant or breastfeeding, or have been through menopause. Ask to see a specialist (like a breast surgeon) if you’re concerned.

IBC grows and spreads quickly, so the cancer may have already spread to nearby lymph nodes by the time symptoms are noticed. This spread can cause swollen lymph nodes under your arm or above your collar bone. If the diagnosis is delayed, the cancer can spread to distant sites.

**How is inflammatory breast cancer diagnosed?**

**Imaging tests**

If inflammatory breast cancer (IBC) is suspected, one or more of the following imaging tests may be done:

- Mammogram
- Breast ultrasound
- Breast MRI (magnetic resonance imaging) scan

Often a photo of the breast is taken to help record the amount of redness and swelling before starting treatment.

**Biopsy**

Inflamatory breast cancer is diagnosed by a biopsy, taking out a small piece of the breast tissue and looking at it in the lab. This might mean a punch biopsy of the breast skin that is abnormal. Your physical exam and other tests may show findings that are "suspicious for" IBC, but only a biopsy can tell for sure that it is cancer.

**Tests on biopsy samples**

The cancer cells in the biopsy will be examined in the lab to determine their grade.

They will also be tested for certain proteins that help decide which treatments will be
helpful. Women whose breast cancer cells have hormone receptors are likely to benefit from treatment with hormone therapy drugs.

Cancer cells that make too much of a protein called HER2 or too many copies of the gene for that protein may be treated by certain drugs that target HER2.

In certain cases, other gene mutations (changes) or proteins might be tested for to see if specific drugs might be helpful.

Stages of inflammatory breast cancer

All inflammatory breast cancers start as Stage III (T4dNXM0) since they involve the skin. If the cancer has spread outside the breast to distant areas it is stage IV.

For more information, read about breast cancer staging.

Survival rates for inflammatory breast cancer

Inflammatory breast cancer (IBC) is considered an aggressive cancer because it grows quickly, is more likely to have spread at the time it’s found, and is more likely to come back after treatment than other types of breast cancer. The outlook is generally not as good as it is for other types of breast cancer.

Survival rates can give you an idea of what percentage of people with the same type and stage of cancer are still alive a certain amount of time (usually 5 years) after they were diagnosed. They can’t tell you how long you will live, but they may help give you a better understanding of how likely it is that your treatment will be successful.

Keep in mind that survival rates are estimates and are often based on previous outcomes of large numbers of people who had a specific cancer, but they can’t predict what will happen in any particular person’s case. These statistics can be confusing and may lead you to have more questions. Talk with your doctor about how these numbers may apply to you, as he or she is familiar with your situation.

What is a 5-year relative survival rate?

A relative survival rate compares women with the same type and stage of breast cancer to women in the overall population. For example, if the 5-year relative survival rate for a specific stage of breast cancer is 70%, it means that women who have that cancer are, on average, about 70% as likely as women who don’t have that cancer to
live for at least 5 years after being diagnosed.

**Where do these numbers come from?**

The American Cancer Society relies on information from the Surveillance, Epidemiology, and End Results (SEER) database, maintained by the National Cancer Institute (NCI), to provide survival statistics for different types of cancer.

The SEER database tracks 5-year relative survival rates for breast cancer in the United States, based on how far the cancer has spread. The SEER database, however, does not group cancers by AJCC TNM stages\(^\text{11}\) (stage 1, stage 2, stage 3, etc.). Instead, it groups cancers into localized, regional, and distant stages:

- **Localized:** There is no sign that the cancer has spread outside of the breast.
- **Regional:** The cancer has spread outside the breast to nearby structures or lymph nodes.
- **Distant:** The cancer has spread to distant parts of the body such as the lungs, liver or bones.

### 5-year relative survival rates for inflammatory breast cancer

(These numbers are based on women diagnosed with inflammatory breast cancer between 2009 and 2016. There is no localized SEER stage for IBC since they are all at least an advanced stage when first diagnosed.)

<table>
<thead>
<tr>
<th>SEER Stage</th>
<th>5-year Relative Survival Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regional</td>
<td>56%</td>
</tr>
<tr>
<td>Distant</td>
<td>19%</td>
</tr>
<tr>
<td>All SEER Stages</td>
<td>41%</td>
</tr>
</tbody>
</table>

**Understanding the numbers**

- **Women now being diagnosed with inflammatory breast cancer may have a better outlook than these numbers show.** Treatments improve over time, and these numbers are based on women who were diagnosed and treated at least four to five years earlier.
- **These numbers apply only to the stage of the cancer when it is first diagnosed.** They do not apply later on if the cancer grows, spreads, or comes back after treatment.
These numbers don’t take everything into account. Survival rates are grouped based on how far the cancer has spread, but your age, overall health, how well the cancer responds to treatment, tumor grade, and other factors can also affect your outlook.

Treating inflammatory breast cancer

Inflammatory breast cancer (IBC) that has not spread outside the breast is stage III. In most cases, treatment is chemotherapy first to try to shrink the tumor, followed by surgery to remove the cancer. Radiation and often other treatments, like more chemotherapy or targeted drug therapy, are given after surgery. Because IBC is so aggressive, breast conserving surgery (lumpectomy) and sentinel lymph node biopsy are typically not part of the treatment.

IBC that has spread to other parts of the body (stage IV) may be treated with chemotherapy, hormone therapy, and/or targeted drugs.

For details, see Treatment of Inflammatory Breast Cancer.

Hyperlinks

4. www.cancer.org/treatment/understanding-your-diagnosis/tests/mri-for-cancer.html


References


Angiosarcoma of the Breast

Angiosarcoma is a rare cancer that starts in the cells that line blood vessels or lymph vessels. Many times it's a complication of previous radiation treatment to the breast. It can happen 8-10 years after getting radiation treatment to the breast.

Signs and symptoms of angiosarcoma

Angiosarcoma can cause skin changes like purple colored nodules and/or a lump in the
breast. It can also occur in the affected arms of women with lymphedema, but this is not common. (Lymphedema¹ is swelling that can develop after surgery or radiation therapy to treat breast cancer.)

**How is angiosarcoma of the breast diagnosed?**

One or more of the following imaging tests may be done to check for breast changes:

- **Diagnostic mammogram**²
- **Breast ultrasound**³
- **Breast MRI (magnetic resonance imaging) scan**⁴

Angiosarcoma is diagnosed by a biopsy⁵, removing a small piece of the breast tissue and looking at it closely in the lab. Only a biopsy can tell for sure that it is cancer.

**Treating angiosarcoma**

Angiosarcomas tend to grow and spread quickly. Treatment usually includes surgery⁶ to remove the breast (mastectomy). The axillary lymph nodes are typically not removed. Radiation⁷ might be given in certain cases of angiosarcomas that are not related to prior breast radiation. For more information on sarcomas, see [Soft Tissue Sarcoma]⁸.

**Hyperlinks**

References


Last Revised: November 19, 2021

Paget Disease of the Breast

Paget disease of the breast is a rare type of breast cancer involving the skin of the nipple and the areola (the dark circle around the nipple). Paget disease usually affects only one breast. In 80-90% of cases, it’s usually found along with either ductal carcinoma in situ (DCIS) or infiltrating ductal carcinoma (invasive breast cancer).

Signs and symptoms of Paget disease of the breast
The skin of the nipple and areola often looks crusted, scaly, and red. There may be blood or yellow fluid coming out of the nipple. Sometimes the nipple looks flat or inverted. It also might burn or itch. Your doctor might try to treat this as eczema first, and if it does not improve, recommend a biopsy.

**How is Paget disease of the breast diagnosed?**

Most people with Paget disease of the breast also have tumors in the same breast. One or more of the following imaging tests may be done to check for other breast changes:

- [Diagnostic mammogram](www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/mammograms.html)
- [Breast MRI (magnetic resonance imaging) scan](www.cancer.org/treatment/understanding-your-diagnosis/tests/mri-for-cancer.html)

Paget disease of the breast is diagnosed by a biopsy, removing a small piece of the breast tissue and looking at it closely in the lab. In some cases, the entire nipple may be removed. Only a biopsy can show for sure that it is cancer.

**Treating Paget disease of the breast**

Paget disease can be treated by removing the entire breast ([mastectomy](www.cancer.org/cancer/breast-cancer/treatment/understanding-your-treatment/mastectomy-or-double-mastectomy.html)) or [breast-conserving surgery](www.cancer.org/cancer/breast-cancer/treatment/understanding-your-treatment/breast-conserving-surgery.html) (BCS) followed by whole-breast [radiation therapy](www.cancer.org/cancer/breast-cancer/treatment/understanding-your-treatment/radiation-therapy.html). If BCS is done, the entire nipple and areola area also needs to be removed. If invasive cancer is found, the lymph nodes under the arm will be checked for cancer.

If no lump is felt in the breast tissue, and your biopsy results show the cancer has not spread within the breast tissue, the outlook (prognosis) is excellent.

If the cancer has spread within the breast tissue (is invasive), the outlook is not as good, and the cancer will be [staged](www.cancer.org/cancer/breast-cancer/treatment/understanding-your-treatment/breast-cancer-staging-and-prognosis.html) and treated like any other [invasive ductal carcinoma](www.cancer.org/cancer/breast-cancer/treatment/understanding-your-treatment/invasive-ductal-carcinoma.html).

**Hyperlinks**

3. [www.cancer.org/treatment/understanding-your-diagnosis/tests/mri-for-cancer.html](www.cancer.org/treatment/understanding-your-diagnosis/tests/mri-for-cancer.html)

References


Last Revised: November 19, 2021

Key Statistics for Breast Cancer
How common is breast cancer?

Breast cancer is the most common cancer in women in the United States, except for skin cancers. It is about 30% (or 1 in 3) of all new female cancers each year.

The American Cancer Society's estimates for breast cancer in the United States for 2021 are:

- About 281,550 new cases of invasive breast cancer will be diagnosed in women.
- About 49,290 new cases of ductal carcinoma in situ (DCIS) will be diagnosed.
- About 43,600 women will die from breast cancer.

Breast cancer mainly occurs in middle-aged and older women. The median age at the time of breast cancer diagnosis is 62. This means half of the women who developed breast cancer are 62 years of age or younger when they are diagnosed. A very small number of women diagnosed with breast cancer are younger than 45.

Lifetime chance of getting breast cancer

Overall, the average risk of a woman in the United States developing breast cancer sometime in her life is about 13%. This means there is a 1 in 8 chance she will develop breast cancer. This also means there is a 7 in 8 chance she will never have the disease.

Trends in breast cancer incidence

In recent years, incidence rates have increased by 0.5% per year.

Trends in breast cancer deaths

Breast cancer is the second leading cause of cancer death in women. (Only lung cancer kills more women each year.) The chance that a woman will die from breast cancer is about 1 in 39 (about 2.6%).

Since 2007, breast cancer death rates have been steady in women younger than 50, but have continued to decrease in older women. From 2013 to 2018, the death rate went down by 1% per year.

These decreases are believed to be the result of finding breast cancer earlier through screening and increased awareness, as well as better treatments.
Differences by race and ethnicity

Some variations in breast cancer can be seen between racial and ethnic groups. For example,

- The median age of diagnosis is slightly younger for Black women (60 years old) compared to White women (63 years old).
- Black women have the highest death rate from breast cancer. This is thought to be partially because about 1 in 5 Black women with breast cancer have triple-negative breast cancer - more than any other racial/ethnic group.
- Black women have a higher chance of developing breast cancer before the age of 40 than White women.
- At every age, Black women are more likely to die from breast cancer than any other race or ethnic group.
- White and Asian/Pacific Islander women are more likely to be diagnosed with localized breast cancer than Black, Hispanic, and American Indian/Alaska Native women.
- Asian/Pacific Islanders have the lowest death rate from breast cancer.
- American Indian/Alaska Natives have the lowest rates of developing breast cancer.

Breast cancer survivors

At this time there are more than 3.8 million breast cancer survivors in the United States. This includes women still being treated and those who have completed treatment.

Survival rates are discussed in Survival Rates for Breast Cancer\(^1\).

Visit the American Cancer Society’s Cancer Statistics Center\(^2\) for more key statistics.

Hyperlinks

2. [cancerstatisticscenter.cancer.org/#/]

References
What’s New in Breast Cancer Research?

Researchers around the world are working to find better ways to prevent, detect, and treat breast cancer, and to improve the quality of life of patients and survivors.

Breast cancer causes

Studies continue to uncover lifestyle factors and habits, as well as inherited genes, that affect breast cancer risk. Here are a few examples:

- Several studies are looking at the effect of exercise, weight gain or loss, and diet on risk.
- Studies on the best use of genetic testing for breast cancer mutations continue.
- Scientists are exploring how common gene variations (small changes in genes that are not as significant as mutations) may affect breast cancer risk. Gene variants typically have only a modest effect on risk, but when taken together they could possibly have a large impact.
• Possible environmental causes of breast cancer have also received more attention in recent years. While much of the science on this topic is still in its earliest stages, this is an area of active research.

Reducing breast cancer risk

Researchers continue to look for medicines that might help lower breast cancer risk, especially women who are at high risk.

• Estrogen blocking drugs are typically used to help treat breast cancer, but some might also help prevent it. Tamoxifen and raloxifene have been used for many years to prevent breast cancer. More recent studies with another class of drugs called aromatase inhibitors (exemestane and anastrozole) have shown that these drugs are also very effective in preventing breast cancer
• Other clinical trials are looking at non-hormonal drugs for breast cancer reduction. Drugs of interest include drugs for diabetes like metformin, drugs used to treat blood or bone marrow disorders, like ruxolitinib, and bexarotene, a drug that treats a specific type of T-cell lymphoma.

This type of research takes many years. It might be some time before meaningful results on any of these compounds are available.

New lab tests

Liquid biopsies

Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA)

Circulating tumor cells (CTCs) are cancer cells that break away from the tumor and move into the bloodstream. Circulating tumor DNA (ctDNA) is DNA that is released into the bloodstream when cancer cells die. Researchers are investigating tests that measure the amount of CTCs and ctDNA in the blood of women with breast cancer. Identifying and testing the CTCs and ctDNA in the blood is sometimes referred to as a “liquid biopsy.” This type of biopsy may offer an easier and less expensive way to test the tumor than a traditional needle biopsy, which comes with risks such as bleeding and infection.
Some studies have shown that in women with metastatic (Stage 4) breast cancer, a high level of CTCs might predict a poorer outcome compared to women with a lower level.

Although more studies are needed before liquid biopsies could replace the traditional needle biopsy, some potential uses include:

- Looking for new gene changes (mutations) in the tumor cells that might mean the cancer has become resistant to specific treatments (like aromatase inhibitors)
- Determining if a certain drug will work on a tumor before trying it
- Helping decide if a woman's cancer is responding to a certain treatment by noticing a decline in CTC level
- Predicting if the breast cancer will recur (come back) in women with early stage breast cancer

**New imaging tests**

Newer types of tests are being developed for breast imaging. Some of these are already being used in certain situations, while others are still being studied. It will take time to see if they are as good as or better than those used today. Some of these tests include:

- Scintimammography (molecular breast imaging)
- Positron emission mammography (PEM)
- Electrical impedance imaging (EIT)
- Elastography
- New types of optical imaging tests

For more on these tests, see [Newer and Experimental Breast Imaging Tests](#) 1

**Breast cancer treatment**

**Chemotherapy**

It is known that chemotherapy can be helpful for many breast cancer patients. But predicting who will benefit the most or the least is still being studied. Sometimes there are significant side effects (long- and short-term) from chemotherapy, so having tests that can determine who really needs chemo would be useful. Many studies are being done to evaluate different tests that can more accurately tell which patients would
benefit from chemo and which patients could avoid it.

**Triple-negative breast cancer**

Since triple-negative breast cancers (TNBC) cannot be treated with hormone therapy or targeted therapy such as HER2 drugs, the treatment options are limited to chemotherapy. And although TNBC tends to respond well to initial chemotherapy, it tends to come back (recur) more frequently than other breast cancers.

In 2019, the immunotherapy drug Atezolizumab (Tecentriq), was approved along with the chemotherapy drug nab-paclitaxel (Abraxane) for use in women with advanced triple negative breast cancer that makes the PD-L1 protein. Other potential targets for new breast cancer drugs have been identified in recent years. Drugs based on these targets, such as kinase inhibitors, are now being studied to treat triple-negative breast cancers, either by themselves, or in combination with chemotherapy. One example is the AKT inhibitor ipatasertib, which, when used with paclitaxel, shows promising results in treating women with TNBC as the first treatment. Another AKT inhibitor, capivasertib, is also showing encouraging results when given with paclitaxel.

**Androgen receptor inhibitors**

Breast cancer cells are routinely tested for estrogen and progesterone receptors to help determine treatment options. About 60% of breast cancer cells also have receptors for androgens (male hormones). Initial studies in women with breast cancer show some response when using the antiandrogen bicalutamide, to treat TNBC that has the androgen receptor. Bicalutamide is a drug that has been used to treat prostate cancer for many years. More studies in breast cancer are ongoing.

**Supportive care**

There are trials looking at different medicines to try and improve memory and [brain symptoms after chemotherapy](#). Other studies are evaluating if certain cardiac drugs, known as beta-blockers, can prevent the heart damage sometimes caused by common breast cancer drugs such as doxorubicin and trastuzumab.

**Thinking about taking part in a clinical trial**

Clinical trials are carefully controlled research studies that are done to get a closer look at promising new treatments or procedures. Clinical trials are one way to get state-of-the-art cancer treatment. In some cases, they may be the only way to get access to
newer treatments. They are also the best way for doctors to learn better methods to treat cancer. Still, they are not right for everyone.

If you would like to learn more about clinical trials that might be right for you, start by asking your doctor if your clinic or hospital conducts clinical trials, or see Clinical Trials to learn more.

**Hyperlinks**


**References**


Ignatiadis M, Lee M, and Jeffrey SS. Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility. *Clin Cancer Res*; 21(21); 4786–800.


Savard MF, Khan O, Hunt KK, Verma S. Redrawing the Lines: The Next Generation of


Written by


Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy ([staging.cancer.org/about-us/policies/content-usage.html](http://staging.cancer.org/about-us/policies/content-usage.html)).